Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

Stocks Climb on Solid Corporate Earnings Results

The S&P 500 Index ($SPX ) (SPY ) today is up +0.67%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.32%. March E-mini S&P futures (ESH25 ) are up by +0.71%, and March E-mini Nasdaq...

Barchart

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up

AbbVie is on track to sustain growth in the wake of Humira's patent cliff and the forecasts are too low. Investors can look forward to an upgrade cycle in 2025.

MarketBeat

Stocks Climb on Apple Earnings Results and Benign US Inflation News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.85%. March E-mini S&P futures (ESH25 ) are up by +0.42%, and March E-mini Nasdaq...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Index Futures Climb as Apple and Intel Provide a Boost, U.S. PCE Inflation Data in Focus

March S&P 500 E-Mini futures (ESH25) are up +0.46%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.73% this morning as solid earnings from Apple and Intel buoyed sentiment, while investors geared up for the release of the Federal Reserve’s first-line inflation gauge.

Barchart

3 Recession-Proof Dividend Stocks To Buy Today

Companies with long track records of increasing dividends can be a sound way to generate income in retirement. There's three top companies to look at today.

Barchart

AbbVie's Quarterly Earnings Preview: What You Need to Know

Pharma giant AbbVie is gearing up to announce its fourth-quarter results later this month and analysts expect a double-digit drop in earnings.

Barchart

2 Dividend Stocks You Can’t Miss in 2025

These companies are well-established with a solid track record of earnings growth and can cushion your portfolio with stability.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

3 Highest-Yielding Dividend Kings To Buy Today

Start your New Year early by exploring high-yield Dividend Kings with decades of growth, top analyst ratings, and attractive yields for long-term investors.

Barchart

Parkinson's disease symptoms reduced by drug in late-stage trial

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose.

Fortune

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 10 unusual trades.

Benzinga

Is AbbVie Stock Underperforming the Dow?

AbbVie has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Benzinga

Pharma giant taken to court after breast implant recall

Patients allegedly exposed to a higher cancer risk from 'defective' breast implants that have now been recalled are suing a pharmaceutical firm seeking damages.

AAP

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Leerink believes the recent selloff has made valuations attractive.

Benzinga

Spotlight on AbbVie: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:ABBV).

Benzinga

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

Benzinga

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Market Whales and Their Recent Bets on ABBV Options

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Barchart

3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

Barchart

Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday settled mixed, with the S&P 500 and the Dow Jones Industrials...

Barchart

Is This Dividend King a Buy After a Strong Q3 Report?

This might be the perfect opportunity to buy this growth and income stock at a discount.

Barchart

Stocks Rally on Optimism in President-Elect Trump’s Policies

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.07%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

Barchart

S&P 500 and Dow Jones Industrials at Record Highs as the Post-Election Rally Continues

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

Barchart

Are Wall Street Analysts Bullish on AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Dow Jones Industrials

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.